Back to Search
KEVIN SMALLEY, D.O.
D.O.
Family Medicine Physician
NPI: 1548619943IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
5101022547(MI)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
MICHIGAN STATE UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE
Class of 2016
Research & Publications (20)
Understanding melanoma signaling networks as the basis for molecular targeted therapy.
PMID 19571822·J Invest Dermatol·2010
8-other
Preclinical and clinical development of targeted therapy in melanoma: attention to schedule.
PMID 19619259·Pigment Cell Melanoma Res·2009
8-other
Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
PMID 19624312·Pigment Cell Melanoma Res·2009
8-other
c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
PMID 19283671·Histol Histopathol·2009
6-review
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
PMID 19663727·Future Oncol·2009
7-preclinical
Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.
PMID 19351826·Cancer Res·2009
6-review
Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
PMID 19156138·Br J Cancer·2009
6-review
Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy.
PMID 19089923·Int J Cancer·2009
6-review
Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice.
PMID 19486528·Respir Res·2009
7-preclinical
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
PMID 18794803·Oncogene·2009
8-other
An active role of the DeltaN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate.
PMID 19461998·PLoS One·2009
7-preclinical
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
PMID 18632627·Cancer Res·2008
7-preclinical
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.
PMID 18790767·Mol Cancer Ther·2008
7-preclinical
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.
PMID 18484710·ACS Chem Biol·2008
8-other
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
PMID 18172275·Clin Cancer Res·2008
7-preclinical
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
PMID 18287029·Proc Natl Acad Sci U S A·2008
4-observational
Similar biological activities of two isostructural ruthenium and osmium complexes.
PMID 18425743·Chemistry·2008
8-other
The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis.
PMID 18439605·Gastroenterology·2008
8-other
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
PMID 18483309·Mol Cancer Ther·2008
8-other
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
PMID 18790768·Mol Cancer Ther·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 1445 SHELDON RD, STE 300
GRAND HAVEN, MI 49417 - Phone
- (616) 296-1500
Quick Facts
- NPI
- 1548619943
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 10
- Publications
- 20
Are you this provider?
Claim Your Profile